While generalist investor interest in biotech is returning, it's not the speculative frenzy of the past. They are avoiding high-risk, early-stage companies and concentrating investments in larger, more understandable, near-commercial businesses like Revolution Medicines, which offer a clearer path to profitability.

Synnovation's deal structure allows it to sell a single oncology asset for a large return to VCs, while the core drug discovery team remains to advance the rest of the pipeline. This 'hive-off' model offers a compelling alternative to traditional M&A or IPO exits.

A third of small-to-mid-cap biotech firms are becoming profitable, with cash reserves projected to soar from $15B in 2025 to over $130B by 2030. This financial strength, combined with large-cap patent expirations, positions them not just as acquisition targets but as potential players in the M&A landscape themselves.

Mergers and acquisitions are more than just exits for private biotech companies. They are the primary mechanism for returning capital to venture capitalists and LPs, who then reinvest those funds back into the ecosystem, fueling the next generation of innovative startups.

VC Bob Nelsen argues that even if large pharma companies appropriate ideas or gain leverage over US biotech, their financial success is ultimately beneficial. Profitable pharma companies must deploy massive cash reserves, much of which flows back into the biotech ecosystem through M&A, funding the next generation.

The old assumption that small biotechs struggle with commercialization ("short the launch") is fading. Acquirers now target companies like Verona and Intracellular that have already built successful sales operations. This de-risks the acquisition by proving the drug's market viability before the deal, signaling a maturation of the biotech sector.

An M&A "super cycle" is unlikely because the most attractive targets—companies with successful assets—are increasingly choosing to "go it alone." Inspired by companies like Vertex and Regeneron, they are shrinking the pool of willing sellers.

The current biotech bull market is fundamentally different from past rallies. It's driven by small and mid-sized companies successfully launching products and generating revenue, shifting the sector from a "dream-based" industry to one focused on execution and profitability.

A healthy biotech IPO market won't reappear independently. It requires a robust M&A landscape first, which attracts generalist investors back to the sector and provides the necessary market liquidity to successfully support new public offerings.